Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 238 results for headache

  1. Transvenous embolisation for spontaneous intracranial hypotension caused by a cerebrospinal fluid–venous fistula (HTG777)

    Evidence-based recommendations on transvenous embolisation for spontaneous intracranial hypotension caused by a cerebrospinal fluid–venous fistula. This involves inserting a catheter through the femoral vein and injecting embolisation liquid to seal the fistula.

    HealthTech guidance
    Published
    15 April 2026

    Sections for HTG777

  2. Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)

    Evidence-based recommendations on burosumab (Crysvita) for X-linked hypophosphataemia in children and young people.

    Highly specialised technologies guidance
    Last updated
    8 April 2025
    View recommendations

    Sections for HST8

  3. Galcanezumab for preventing cluster headache [ID1212]

    Discontinued Reference number: GID-TA10425

    Technology appraisal guidance
    Discontinued

  4. Postural hypotension in adults: fludrocortisone (ESUOM20)

    Summary of the evidence on fludrocortisone for treating postural hypotension in adults to inform local NHS planning and decision-making

    Evidence summary
    Published
    1 October 2013

  5. Velmanase alfa for treating alpha-mannosidosis (HST29)

    Evidence-based recommendations on velmanase alfa (Lamzede) for treating alpha-mannosidosis in people under 18 years and in people who turn 18 while on treatment.

    Highly specialised technologies guidance
    Published
    13 December 2023
    View recommendations

    Sections for HST29

  6. Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infections (ES39)

    Summary of the evidence on oritavancin for acute bacterial skin and skin structure infections (ABSSSI) in adults

    Evidence summary
    Published
    11 May 2022

  7. Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)

    Evidence-based recommendations on abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel) and tocilizumab (RoActemra) for treating juvenile idiopathic arthritis in children, young people and adults.

    Technology appraisal guidance
    Published
    16 December 2015
    View recommendations

    Sections for TA373

  8. Polycystic ovary syndrome: metformin in women not planning pregnancy (ESUOM6)

    Summary of the evidence on metformin for polycystic ovary syndrome (PCOS) in women not planning pregnancy to inform local NHS planning and decision-making

    Evidence summary
    Published
    21 February 2013

  9. Narcolepsy with or without cataplexy in adults: pitolisant (ES8)

    Summary on the evidence on pitolisant for treating narcolepsy with or without cataplexy to inform local NHS planning and decision-making

    Evidence summary
    Published
    14 March 2017

  10. Gastro-oesophageal reflux disease and dyspepsia in adults. Patient decision aid on an option grid to help people make decisions about long term heartburn treatment

    have side effects from the medicine. The most common mild side effects are headache, abdominal pain, nausea, diarrhoea, vomiting, and...

  11. Metreleptin for treating lipodystrophy (HST14)

    Evidence-based recommendations on metreleptin (Myalepta) for treating lipodystrophy in children and adults.

    Highly specialised technologies guidance
    Published
    24 February 2021
    View recommendations

    Sections for HST14

  12. Further research studies into deep brain stimulation (DBS) for intractable trigeminal autonomic cephalalgias (TACs) should clearly define patient selection and report the intensity and duration of stimulation, medication use and quality of life, in addition to documenting the effects on headache symptoms as clearly as possible.

    medication use and quality of life, in addition to documenting the effects on headache symptoms as clearly as possible. Any explanatory...

    Research recommendation
    Published
    9 June 2015

  13. Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)

    Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making

    Evidence summary
    Published
    1 March 2016

  14. Bile acid malabsorption: colesevelam (ESUOM22)

    Summary of the evidence on colesevelam for treating bile acid malabsorption (BAM) to inform local NHS planning and decision-making

    Evidence summary
    Published
    29 October 2013

  15. Lumbar subcutaneous shunt (HTG41)

    Evidence-based recommendations on lumbar subcutaneous shunt. This involves using a shunt to drain excess cerebrospinal fluid away so that it doesn’t damage the brain or eyes.

    HealthTech guidance
    Published
    23 June 2004
    View recommendations

    Sections for HTG41